benzo[1,3]dioxol-5-ylmethyl-tert-butylamine | 207350-17-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: benzo[1,3]dioxol-5-ylmethyl-tert-butylamine
• 英文别名: N-(1,3-benzodioxol-5-ylmethyl)-2-methylpropan-2-amine
• CAS: 207350-17-2
• 化学式: C₁₂H₁₇NO₂
• mdl: MFCD01427011
• 分子量: 207.272
• InChiKey: HWIUEWPYNOGTJO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  benzo[1,3]dioxol-5-ylmethyl-tert-butylamine 在 titanium(III) chloride 、 草酰氯 、 双氧水 、 N,N-二甲基甲酰胺 作用下， 以 甲醇 、 水 、 乙腈 、 苯 为溶剂， 反应 2.17h， 生成 3-benzenesulfinyl-N-benzo[1,3]dioxol-5-ylmethyl-N-tert-butylacrylamide
  参考文献：
  名称：

  Additive and Vinylogous Pummerer Reactions of Amido Sulfoxides and Their Use in the Preparation of Nitrogen Containing Heterocycles

  摘要：

  The alpha-thiocarbocation generated from the Pummerer re action of N-methyl-N-phenyl-2-[2-(toluene-4-sulfinyl)phenyl]acetamide undergoes Friedel-Crafts reaction at the gamma-carbon with the tethered aromatic ring. Reductive removal of the phenylthio group from the resulting product using Raney nickel occurs in high yield, and the overall reaction represents a new method for the synthesis of a variety of 3-phenyl-substituted oxindoles. Treatment of the related N-benzyl-N-alkyl amido sulfoxide system with trifluoroacetic anhydride affords tetrahydroisoquinolone derivatives. The product distribution encountered coincides with the rotamer population of the starting amide. When the N-benzyl-N-methyl amide is used, only the normal Pummerer product is formed. In this case, the thionium ion is generated in the wrong conformation for pi-cyclization to occur. The corresponding N-tert-butyl amido system, however, exists in a geometric orientation which places the benzylic group in the crucial conformation necessary for pi-cyclization, and consequently, the reaction proceeds smoothly. Related cyclization reactions occur in good yield with the corresponding furanyl and cyclohexenyl N-tert-butyl amido sulfoxides. The additive Pummerer reaction of 3-phenylsulfinyl-N-benzyl-N-tert-butylacrylamide gave products derived from both 5- and 6-exo trig cyclizations. Intramolecular electrophilic aromatic substitution via six-membered ring closure ultimately afforded a dihydropyridone. The competitive process involving ipso attack of the aromatic ring on the thionium ion generates a spiro cyclohexadienyl cation that undergoes fragmentation of the adjacent a-bond. The resulting acyl iminium ion is converted to N-tert-butyl-2-phenyl-3-phenylsulfinylacrylamide upon aqueous workup. Only cyclizations leading to five-membered rings occur with the corresponding indolyl and alkenyl N-tert-butyl amido sulfoxides.

  DOI：

  10.1021/jo972093h
• 作为产物：
  描述：

  胡椒醛 、 叔丁胺 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 生成 benzo[1,3]dioxol-5-ylmethyl-tert-butylamine
  参考文献：
  名称：

  一种鲁棒钯（II） -卟啉配合物为催化剂的可见光诱导的氧化Ç ？H功能化

  摘要：

  已经合成了一系列显示双发射且寿命高达437μs的钯（II）-卟啉配合物。在这四种络合物，PDF 20 TPP为光致氧化℃的高效且健壮的催化剂通过使用氧气作为氧化剂终端ħ官能化。通过对PdF 20 TPP的混合物进行光辐照（λ > 400 nm），可以得到高至极好产率的α-官能化叔胺，叔胺和亲核试剂（氰化物，硝基甲烷，丙二酸二甲酯，亚磷酸二乙酯和丙酮）在有氧条件下。可以类似地制备分子内环化胺化合物的四个实例。光化学反应前后的紫外可见吸收光谱比较表明，PdF 20 TPP具有很高的耐受性（回收率> 95％）。PdF 20 TPP的实际应用已通过使用低催化剂负载量（0.01 mol％）并以10 mmol规模进行的光化学反应得以揭示。该PDF 20 TPP催化剂可以优异的收率使光诱导的硫化物氧化为亚砜。机理研究表明，光催化通过单线态氧氧化进行。

  DOI：

  10.1002/chem.201203774

文献信息

• MODULATORS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE
  申请人：Durand-Reville Thomas

  公开号：US20110021513A1

  公开（公告）日：2011-01-27

  The present invention relates to modulators of IRAK kinase and provides compositions comprising such modulators, as well as methods therewith for treating conditions or diseases mediated by or associated with IRAK kinase.

  本发明涉及IRAK激酶的调节剂，并提供包含这些调节剂的组合物，以及利用这些调节剂治疗由IRAK激酶介导或相关的疾病或病症的方法。
• ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF
  申请人：Ohno Michihiro

  公开号：US20100016319A1

  公开（公告）日：2010-01-21

  This invention relates to a pharmaceutical comprising as an effective ingredient an arylmethylene urea exemplified by the following formula: or a pharmaceutically acceptable salt thereof. The arylmethylene urea and the pharmaceutically acceptable salts thereof are useful for therapy or prophylaxis of inflammatory bowel disease and overactive bladder.

  本发明涉及一种药物，其有效成分为以下式子所示的芳基亚甲基脲或其药学上可接受的盐： 该芳基亚甲基脲及其药学上可接受的盐可用于治疗或预防炎症性肠病和过度活跃的膀胱。
• Androgen Receptor Modulators
  申请人：Wang Jiabing

  公开号：US20070269405A1

  公开（公告）日：2007-11-22

  Compounds of structural Formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

  结构式（I）的化合物以组织选择性的方式调节雄激素受体（AR），在增强肌肉张力和治疗由雄激素缺乏引起的或可以通过雄激素治疗改善的疾病中有用，包括骨质疏松症，骨质疏松症，糖皮质激素诱导的骨质疏松症，牙周病，骨折，骨重建手术后的骨损伤，肌肉萎缩，虚弱，老化皮肤，男性性腺功能减退，女性绝经后症状，动脉粥样硬化，高胆固醇血症，高脂血症，肥胖症，再生障碍性贫血和其他造血系统疾病，炎性关节炎和关节修复，艾滋病浪费，前列腺癌，良性前列腺增生症（BPH），腹部脂肪堆积，代谢综合征，2型糖尿病，癌症恶病质，阿尔茨海默病，肌肉萎缩症，认知能力下降，性功能障碍，睡眠呼吸暂停，抑郁症，早发卵巢衰竭和自身免疫疾病，单独或与其他活性药物联合使用。
• New neurokinin antagonists for use as medicaments
  申请人：Albert Scott Jeffrey

  公开号：US20070021406A1

  公开（公告）日：2007-01-25

  The present application relates to internally cyclized naphthamide compounds of the formula Ia (wherein R 1a , R 1b , R 1c , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , X 1 , X 2 , Y, Z, and n are as defined herein), which are useful, for example, for antagonizing the pharmacological actions of the neurokinin 1 (NK 1 ) receptor. In particular, these compounds are useful in the treatment of diseases in which Substance P is involved such as, for example, major depressive disorder, severe anxiety disorders, stress disorders, major depressive disorder with anxiety, eating disorders, bipolar disorder, substance use disorder, schizophrenic disorders, psychotic disorders, movement disorders, cognitive disorders, depression and/or anxiety, mania or hypomania, aggressive behaviour, obesity, rheumatoid arthritis, Alzheimer's disease, cancer, oedema, allergic rhinitis, inflammation, pain, gastrointestinal-hypermotility, Huntington's disease, chronic obstructive pulmonary disorder (COPD), hypertension, migraine, bladder hypermotility, and urticaria.

  本申请涉及公式Ia的内环化萘酰胺化合物（其中R1a，R1b，R1c，R2，R3，R4，R5，R6，R7，R8，X1，X2，Y，Z和n的定义如本文所述），这些化合物可用于拮抗神经激肽1（NK1）受体的药理作用。特别地，这些化合物可用于治疗与物质P有关的疾病，例如重度抑郁障碍、严重焦虑障碍、应激障碍、伴有焦虑的重度抑郁障碍、进食障碍、躁狂障碍、物质使用障碍、精神分裂障碍、精神病性障碍、运动障碍、认知障碍、抑郁和/或焦虑、狂躁或亢进行为、肥胖症、类风湿性关节炎、阿尔茨海默病、癌症、水肿、过敏性鼻炎、炎症、疼痛、胃肠道高动力性、亨廷顿病、慢性阻塞性肺疾病（COPD）、高血压、偏头痛、膀胱高动力性和荨麻疹。
• COMPOUNDS FOR TREATING PULMONARY HYPERTENSION
  申请人：Klein Martina

  公开号：US20100113452A1

  公开（公告）日：2010-05-06

  The present invention relates to pharmaceutical compositions and combinations for treating, preventing or managing pulmonary hypertension comprising small molecule heterocyclic pharmaceuticals, and more particularly, substituted pyridines and pyridazines optionally combined with at least one additional therapeutic agent.

  本发明涉及用于治疗、预防或管理肺动脉高压的制药组合物和组合物，包括小分子杂环类药物，特别是取代的吡啶和吡啶二氮杂环，可选地与至少一种其他治疗剂联合使用。